{"pmid":32237998,"title":"An Assessment of United States Dermatology Practices during the COVID-19 Outbreak.","text":["An Assessment of United States Dermatology Practices during the COVID-19 Outbreak.","Objectives: The COVID-19 outbreak is a serious threat to public health and social distancing on the part of individuals can help contain the epidemic. It is unknown if dermatologists are assisting with the public health officials' recommendations for social distancing by closing their practice or limiting their practice to the treatment of emergency conditions. This study examines the activity level of dermatology practices during the United States COVID-19 outbreak.Methods: We performed scripted phone calls to 60 dermatology practices in six different counties in the United Stated during the COVID-19 outbreak. We assessed if practices are open and if they are serving patients with urgent and non-urgent conditions.Results: Of the 60 dermatologists selected for the study, 55 were successfully contacted (92% contact rate). Of these practices, 29 (53%) were open, 17 (31%) were only seeing urgent patients and 9 (16%) were closed. New York, New York had 2 (20%) open offices which was the lowest proportion of any county (p=.04). Counties with higher prevalence had fewer open offices (p<.01, R(2)=.7).Conclusions: Many practices have restricted their level of operation especially in higher areas of COVID-19 prevalence, likely to help facilitate social distancing.","J Dermatolog Treat","Muddasani, Suraj","Housholder, Anne","Fleischer, Alan B Jr","32237998"],"abstract":["Objectives: The COVID-19 outbreak is a serious threat to public health and social distancing on the part of individuals can help contain the epidemic. It is unknown if dermatologists are assisting with the public health officials' recommendations for social distancing by closing their practice or limiting their practice to the treatment of emergency conditions. This study examines the activity level of dermatology practices during the United States COVID-19 outbreak.Methods: We performed scripted phone calls to 60 dermatology practices in six different counties in the United Stated during the COVID-19 outbreak. We assessed if practices are open and if they are serving patients with urgent and non-urgent conditions.Results: Of the 60 dermatologists selected for the study, 55 were successfully contacted (92% contact rate). Of these practices, 29 (53%) were open, 17 (31%) were only seeing urgent patients and 9 (16%) were closed. New York, New York had 2 (20%) open offices which was the lowest proportion of any county (p=.04). Counties with higher prevalence had fewer open offices (p<.01, R(2)=.7).Conclusions: Many practices have restricted their level of operation especially in higher areas of COVID-19 prevalence, likely to help facilitate social distancing."],"journal":"J Dermatolog Treat","authors":["Muddasani, Suraj","Housholder, Anne","Fleischer, Alan B Jr"],"date":"2020-04-03T11:00:00Z","year":2020,"_id":"32237998","week":"202014|Mar 30 - Apr 05","doi":"10.1080/09546634.2020.1750556","keywords":["epidemic","pandemic","public health","spread"],"source":"PubMed","locations":["United Stated","United States","New York"],"countries":["United States"],"countries_codes":["USA|United States"],"topics":["Prevention"],"weight":1,"_version_":1662996001852489728,"score":7.6048946,"similar":[{"pmid":32240428,"title":"Achieve Research Continuity During Social Distancing by Rapidly Implementing Individual and Group Videoconferencing with Participants: Key Considerations, Best Practices, and Protocols.","text":["Achieve Research Continuity During Social Distancing by Rapidly Implementing Individual and Group Videoconferencing with Participants: Key Considerations, Best Practices, and Protocols.","The novel coronavirus has upended many traditional research procedures as universities and other research entities have closed to activate social distancing. Some social and behavioral research activities (e.g. data analysis, manuscript preparation) can be continued from other environments with appropriate security protocols in place. For studies involving in-person interactions, continuity may be more difficult. Phone-based interactions provide a low-tech solution that may suffice in some cases. Yet, videoconferencing platforms can nearly replicate in-person interactions, activating both auditory and visual senses and potentially resulting in more substantial engagement. Staff can meet with participants individually or in groups, each seeing and hearing one another in real time. This paper provides guidance for researchers transitioning in-person assessments and interventions to a synchronous videoconferencing platform. Best practices, key considerations, examples from the field, and sample protocols are presented to ease transition for ongoing studies and maximize the potential of videoconferencing-and social distancing.","AIDS Behav","Marhefka, Stephanie","Lockhart, Elizabeth","Turner, DeAnne","32240428"],"abstract":["The novel coronavirus has upended many traditional research procedures as universities and other research entities have closed to activate social distancing. Some social and behavioral research activities (e.g. data analysis, manuscript preparation) can be continued from other environments with appropriate security protocols in place. For studies involving in-person interactions, continuity may be more difficult. Phone-based interactions provide a low-tech solution that may suffice in some cases. Yet, videoconferencing platforms can nearly replicate in-person interactions, activating both auditory and visual senses and potentially resulting in more substantial engagement. Staff can meet with participants individually or in groups, each seeing and hearing one another in real time. This paper provides guidance for researchers transitioning in-person assessments and interventions to a synchronous videoconferencing platform. Best practices, key considerations, examples from the field, and sample protocols are presented to ease transition for ongoing studies and maximize the potential of videoconferencing-and social distancing."],"journal":"AIDS Behav","authors":["Marhefka, Stephanie","Lockhart, Elizabeth","Turner, DeAnne"],"date":"2020-04-03T11:00:00Z","year":2020,"_id":"32240428","week":"202014|Mar 30 - Apr 05","doi":"10.1007/s10461-020-02837-x","keywords":["Intervention research","Social distancing","Videoconferencing","ehealth"],"source":"PubMed","topics":["Prevention"],"weight":1,"_version_":1662996001916452864,"score":254.42664},{"pmid":32053579,"pmcid":"PMC7017962","title":"Persons Evaluated for 2019 Novel Coronavirus - United States, January 2020.","text":["Persons Evaluated for 2019 Novel Coronavirus - United States, January 2020.","In December 2019, a cluster of cases of pneumonia emerged in Wuhan City in central China's Hubei Province. Genetic sequencing of isolates obtained from patients with pneumonia identified a novel coronavirus (2019-nCoV) as the etiology (1). As of February 4, 2020, approximately 20,000 confirmed cases had been identified in China and an additional 159 confirmed cases in 23 other countries, including 11 in the United States (2,3). On January 17, CDC and the U.S. Department of Homeland Security's Customs and Border Protection began health screenings at U.S. airports to identify ill travelers returning from Wuhan City (4). CDC activated its Emergency Operations Center on January 21 and formalized a process for inquiries regarding persons suspected of having 2019-nCoV infection (2). As of January 31, 2020, CDC had responded to clinical inquiries from public health officials and health care providers to assist in evaluating approximately 650 persons thought to be at risk for 2019-nCoV infection. Guided by CDC criteria for the evaluation of persons under investigation (PUIs) (5), 210 symptomatic persons were tested for 2019-nCoV; among these persons, 148 (70%) had travel-related risk only, 42 (20%) had close contact with an ill laboratory-confirmed 2019-nCoV patient or PUI, and 18 (9%) had both travel- and contact-related risks. Eleven of these persons had laboratory-confirmed 2019-nCoV infection. Recognizing persons at risk for 2019-nCoV is critical to identifying cases and preventing further transmission. Health care providers should remain vigilant and adhere to recommended infection prevention and control practices when evaluating patients for possible 2019-nCoV infection (6). Providers should consult with their local and state health departments when assessing not only ill travelers from 2019-nCoV-affected countries but also ill persons who have been in close contact with patients with laboratory-confirmed 2019-nCoV infection in the United States.","MMWR Morb Mortal Wkly Rep","Bajema, Kristina L","Oster, Alexandra M","McGovern, Olivia L","Lindstrom, Stephen","Stenger, Mark R","Anderson, Tara C","Isenhour, Cheryl","Clarke, Kevin R","Evans, Mary E","Chu, Victoria T","Biggs, Holly M","Kirking, Hannah L","Gerber, Susan I","Hall, Aron J","Fry, Alicia M","Oliver, Sara E","32053579"],"abstract":["In December 2019, a cluster of cases of pneumonia emerged in Wuhan City in central China's Hubei Province. Genetic sequencing of isolates obtained from patients with pneumonia identified a novel coronavirus (2019-nCoV) as the etiology (1). As of February 4, 2020, approximately 20,000 confirmed cases had been identified in China and an additional 159 confirmed cases in 23 other countries, including 11 in the United States (2,3). On January 17, CDC and the U.S. Department of Homeland Security's Customs and Border Protection began health screenings at U.S. airports to identify ill travelers returning from Wuhan City (4). CDC activated its Emergency Operations Center on January 21 and formalized a process for inquiries regarding persons suspected of having 2019-nCoV infection (2). As of January 31, 2020, CDC had responded to clinical inquiries from public health officials and health care providers to assist in evaluating approximately 650 persons thought to be at risk for 2019-nCoV infection. Guided by CDC criteria for the evaluation of persons under investigation (PUIs) (5), 210 symptomatic persons were tested for 2019-nCoV; among these persons, 148 (70%) had travel-related risk only, 42 (20%) had close contact with an ill laboratory-confirmed 2019-nCoV patient or PUI, and 18 (9%) had both travel- and contact-related risks. Eleven of these persons had laboratory-confirmed 2019-nCoV infection. Recognizing persons at risk for 2019-nCoV is critical to identifying cases and preventing further transmission. Health care providers should remain vigilant and adhere to recommended infection prevention and control practices when evaluating patients for possible 2019-nCoV infection (6). Providers should consult with their local and state health departments when assessing not only ill travelers from 2019-nCoV-affected countries but also ill persons who have been in close contact with patients with laboratory-confirmed 2019-nCoV infection in the United States."],"journal":"MMWR Morb Mortal Wkly Rep","authors":["Bajema, Kristina L","Oster, Alexandra M","McGovern, Olivia L","Lindstrom, Stephen","Stenger, Mark R","Anderson, Tara C","Isenhour, Cheryl","Clarke, Kevin R","Evans, Mary E","Chu, Victoria T","Biggs, Holly M","Kirking, Hannah L","Gerber, Susan I","Hall, Aron J","Fry, Alicia M","Oliver, Sara E"],"date":"2020-02-14T11:00:00Z","year":2020,"_id":"32053579","week":"20207|Feb 10 - Feb 16","doi":"10.15585/mmwr.mm6906e1","source":"PubMed","locations":["China","USA","Hubei","United States","Wuhan"],"countries":["China","United States"],"countries_codes":["CHN|China","USA|United States"],"topics":["Diagnosis","Prevention"],"weight":1,"_version_":1663095626220437504,"score":244.507},{"pmid":32241193,"title":"COVID-19: Challenges and opportunities for dermatology response.","text":["COVID-19: Challenges and opportunities for dermatology response.","As the world faces an unprecedented challenge in the novel coronavirus disease-2019 (COVID-19) pandemic, which as of 21 March 2020 has had 287,239 confirmed cases and 11,921 number of deaths worldwide, its consequences have reached all facets of medicine, including dermatology.(1) It remains a rapidly evolving scenario with guidance being updated regularly to reflect new information. Whilst it presents unique challenges to dermatology, it also presents an opportunity to help drive the development of new infrastructure to adapt and improve dermatology practice.","J Dermatolog Treat","Chawla, S","32241193"],"abstract":["As the world faces an unprecedented challenge in the novel coronavirus disease-2019 (COVID-19) pandemic, which as of 21 March 2020 has had 287,239 confirmed cases and 11,921 number of deaths worldwide, its consequences have reached all facets of medicine, including dermatology.(1) It remains a rapidly evolving scenario with guidance being updated regularly to reflect new information. Whilst it presents unique challenges to dermatology, it also presents an opportunity to help drive the development of new infrastructure to adapt and improve dermatology practice."],"journal":"J Dermatolog Treat","authors":["Chawla, S"],"date":"2020-04-04T11:00:00Z","year":2020,"_id":"32241193","week":"202014|Mar 30 - Apr 05","doi":"10.1080/09546634.2020.1751040","keywords":["COVID-19","outpatient","teledermatology"],"source":"PubMed","weight":0,"_version_":1663079112881733632,"score":219.0989},{"pmid":32245814,"title":"Projecting hospital utilization during the COVID-19 outbreaks in the United States.","text":["Projecting hospital utilization during the COVID-19 outbreaks in the United States.","In the wake of community coronavirus disease 2019 (COVID-19) transmission in the United States, there is a growing public health concern regarding the adequacy of resources to treat infected cases. Hospital beds, intensive care units (ICUs), and ventilators are vital for the treatment of patients with severe illness. To project the timing of the outbreak peak and the number of ICU beds required at peak, we simulated a COVID-19 outbreak parameterized with the US population demographics. In scenario analyses, we varied the delay from symptom onset to self-isolation, the proportion of symptomatic individuals practicing self-isolation, and the basic reproduction number R 0 Without self-isolation, when R 0 = 2.5, treatment of critically ill individuals at the outbreak peak would require 3.8 times more ICU beds than exist in the United States. Self-isolation by 20% of cases 24 h after symptom onset would delay and flatten the outbreak trajectory, reducing the number of ICU beds needed at the peak by 48.4% (interquartile range 46.4-50.3%), although still exceeding existing capacity. When R 0 = 2, twice as many ICU beds would be required at the peak of outbreak in the absence of self-isolation. In this scenario, the proportional impact of self-isolation within 24 h on reducing the peak number of ICU beds is substantially higher at 73.5% (interquartile range 71.4-75.3%). Our estimates underscore the inadequacy of critical care capacity to handle the burgeoning outbreak. Policies that encourage self-isolation, such as paid sick leave, may delay the epidemic peak, giving a window of time that could facilitate emergency mobilization to expand hospital capacity.","Proc Natl Acad Sci U S A","Moghadas, Seyed M","Shoukat, Affan","Fitzpatrick, Meagan C","Wells, Chad R","Sah, Pratha","Pandey, Abhishek","Sachs, Jeffrey D","Wang, Zheng","Meyers, Lauren A","Singer, Burton H","Galvani, Alison P","32245814"],"abstract":["In the wake of community coronavirus disease 2019 (COVID-19) transmission in the United States, there is a growing public health concern regarding the adequacy of resources to treat infected cases. Hospital beds, intensive care units (ICUs), and ventilators are vital for the treatment of patients with severe illness. To project the timing of the outbreak peak and the number of ICU beds required at peak, we simulated a COVID-19 outbreak parameterized with the US population demographics. In scenario analyses, we varied the delay from symptom onset to self-isolation, the proportion of symptomatic individuals practicing self-isolation, and the basic reproduction number R 0 Without self-isolation, when R 0 = 2.5, treatment of critically ill individuals at the outbreak peak would require 3.8 times more ICU beds than exist in the United States. Self-isolation by 20% of cases 24 h after symptom onset would delay and flatten the outbreak trajectory, reducing the number of ICU beds needed at the peak by 48.4% (interquartile range 46.4-50.3%), although still exceeding existing capacity. When R 0 = 2, twice as many ICU beds would be required at the peak of outbreak in the absence of self-isolation. In this scenario, the proportional impact of self-isolation within 24 h on reducing the peak number of ICU beds is substantially higher at 73.5% (interquartile range 71.4-75.3%). Our estimates underscore the inadequacy of critical care capacity to handle the burgeoning outbreak. Policies that encourage self-isolation, such as paid sick leave, may delay the epidemic peak, giving a window of time that could facilitate emergency mobilization to expand hospital capacity."],"journal":"Proc Natl Acad Sci U S A","authors":["Moghadas, Seyed M","Shoukat, Affan","Fitzpatrick, Meagan C","Wells, Chad R","Sah, Pratha","Pandey, Abhishek","Sachs, Jeffrey D","Wang, Zheng","Meyers, Lauren A","Singer, Burton H","Galvani, Alison P"],"date":"2020-04-05T11:00:00Z","year":2020,"_id":"32245814","week":"202014|Mar 30 - Apr 05","doi":"10.1073/pnas.2004064117","keywords":["SARS-CoV-2","critical care need","hospitalization","self-isolation"],"source":"PubMed","locations":["United States","US"],"countries":["United States"],"countries_codes":["USA|United States"],"topics":["Prevention"],"weight":1,"_version_":1663169699658072064,"score":207.54457},{"pmid":32106216,"title":"Update: Public Health Response to the Coronavirus Disease 2019 Outbreak - United States, February 24, 2020.","text":["Update: Public Health Response to the Coronavirus Disease 2019 Outbreak - United States, February 24, 2020.","An outbreak of coronavirus disease 2019 (COVID-19) caused by the 2019 novel coronavirus (SARS-CoV-2) began in Wuhan, Hubei Province, China in December 2019, and has spread throughout China and to 31 other countries and territories, including the United States (1). As of February 23, 2020, there were 76,936 reported cases in mainland China and 1,875 cases in locations outside mainland China (1). There have been 2,462 associated deaths worldwide; no deaths have been reported in the United States. Fourteen cases have been diagnosed in the United States, and an additional 39 cases have occurred among repatriated persons from high-risk settings, for a current total of 53 cases within the United States. This report summarizes the aggressive measures (2,3) that CDC, state and local health departments, multiple other federal agencies, and other partners are implementing to slow and try to contain transmission of COVID-19 in the United States. These measures require the identification of cases and contacts of persons with COVID-19 in the United States and the recommended assessment, monitoring, and care of travelers arriving from areas with substantial COVID-19 transmission. Although these measures might not prevent widespread transmission of the virus in the United States, they are being implemented to 1) slow the spread of illness; 2) provide time to better prepare state and local health departments, health care systems, businesses, educational organizations, and the general public in the event that widespread transmission occurs; and 3) better characterize COVID-19 to guide public health recommendations and the development and deployment of medical countermeasures, including diagnostics, therapeutics, and vaccines. U.S. public health authorities are monitoring the situation closely, and CDC is coordinating efforts with the World Health Organization (WHO) and other global partners. Interim guidance is available at https://www.cdc.gov/coronavirus/index.html. As more is learned about this novel virus and this outbreak, CDC will rapidly incorporate new knowledge into guidance for action by CDC, state and local health departments, health care providers, and communities.","MMWR Morb Mortal Wkly Rep","Jernigan, Daniel B","32106216"],"abstract":["An outbreak of coronavirus disease 2019 (COVID-19) caused by the 2019 novel coronavirus (SARS-CoV-2) began in Wuhan, Hubei Province, China in December 2019, and has spread throughout China and to 31 other countries and territories, including the United States (1). As of February 23, 2020, there were 76,936 reported cases in mainland China and 1,875 cases in locations outside mainland China (1). There have been 2,462 associated deaths worldwide; no deaths have been reported in the United States. Fourteen cases have been diagnosed in the United States, and an additional 39 cases have occurred among repatriated persons from high-risk settings, for a current total of 53 cases within the United States. This report summarizes the aggressive measures (2,3) that CDC, state and local health departments, multiple other federal agencies, and other partners are implementing to slow and try to contain transmission of COVID-19 in the United States. These measures require the identification of cases and contacts of persons with COVID-19 in the United States and the recommended assessment, monitoring, and care of travelers arriving from areas with substantial COVID-19 transmission. Although these measures might not prevent widespread transmission of the virus in the United States, they are being implemented to 1) slow the spread of illness; 2) provide time to better prepare state and local health departments, health care systems, businesses, educational organizations, and the general public in the event that widespread transmission occurs; and 3) better characterize COVID-19 to guide public health recommendations and the development and deployment of medical countermeasures, including diagnostics, therapeutics, and vaccines. U.S. public health authorities are monitoring the situation closely, and CDC is coordinating efforts with the World Health Organization (WHO) and other global partners. Interim guidance is available at https://www.cdc.gov/coronavirus/index.html. As more is learned about this novel virus and this outbreak, CDC will rapidly incorporate new knowledge into guidance for action by CDC, state and local health departments, health care providers, and communities."],"journal":"MMWR Morb Mortal Wkly Rep","authors":["Jernigan, Daniel B"],"date":"2020-02-28T11:00:00Z","year":2020,"_id":"32106216","week":"20209|Feb 24 - Mar 01","doi":"10.15585/mmwr.mm6908e1","source":"PubMed","locations":["China","Wuhan","United States","Hubei","USA"],"countries":["China","United States"],"countries_codes":["CHN|China","USA|United States"],"topics":["Prevention"],"weight":1,"_version_":1662334544226811904,"score":199.56866}]}